PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 17(1): 48-51 1997
© 1997 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coles, G.
Right arrow Articles by de Vos, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coles, G.
Right arrow Articles by de Vos, C
Peritoneal Dialysis International, Vol 17, Issue 1, 48-51
Copyright © 1997 by International Society for Peritoneal Dialysis

Clinical Trial

A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD

GA Coles, R Gokal, C Ogg, F Jani, DT O'Donoghue, GC Cancarini, R Maiorca, A Tranaeus, D Faict, and C de Vos

Cardiff Royal Infimary, Wales.

OBJECTIVE: To evaluate the safety and efficacy of bicarbonate- and bicarbonate/lactate-based PD fluids. DESIGN: A randomly allocated prospective controlled trial lasting eight weeks. SETTING: Five renal units in Europe. PATIENTS: Individuals who have been treated by CAPD for at least three months and who have had at least one month's therapy with 40 mmol/L lactate PD fluid. Those with recent infection, diabetes or other serious illness are excluded. Forty-seven individuals have entered the study so far. INTERVENTIONS: Patients are randomly allocated to three groups. Group 1 receive 40 mmol/L lactate dialysate, Group 2 are given 38 mmol/L bicarbonate fluid and Group 3 are tested with a 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate. OUTCOME MEASURES: The primary outcome measure is the plasma bicarbonate level. Adverse events and ease of use of the two-chambered bags used by Groups 2 and 3 are also being assessed. RESULTS: To date, plasma bicarbonate levels have been the same in all treatment groups up to the end of the trial period. There are no differences in serum lactate levels. No side effects are attributable to the test fluids. The patients have managed the two-chambered bags successfully. CONCLUSION: This trial is still ongoing, but to date, neutral bicarbonate based fluids have been as effective as lactate dialysate in treating uremic acidosis.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Montenegro, R. Saracho, I. Gallardo, I. Martinez, R. Munoz, and N. Quintanilla
Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1703 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. J. Margetts and D. N. Churchill
Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients
J. Am. Soc. Nephrol., November 1, 2002; 13(11): 2787 - 2794.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Jones, C. J. Holmes, R. K. Mackenzie, R. Stead, G. A. Coles, J. D. Williams, D. Faict, and N. Topley
Continuous Dialysis with Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids Results in a Long-Term Improvement in Ex Vivo Peritoneal Macrophage Function
J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S97 - 103.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Gokal
Peritoneal Dialysis in the 21st Century: An Analysis of Current Problems and Future Developments
J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S104 - 115.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1997 by Multimed Inc.